Reproductive Health — MCQs
On this page
A 47-year-old woman with regular menstrual cycles presents with worsening premenstrual mood symptoms including irritability, anxiety and low mood for 10 days before each period, which resolve shortly after menstruation begins. She also experiences moderate hot flushes in the week before her period. She requests effective contraception as she remains sexually active. Her BMI is 27 kg/m² and she has no significant medical history. What is the most appropriate management option?
A 56-year-old woman presents for review of her HRT. She has been taking continuous combined HRT (oral estradiol 2 mg with norethisterone acetate 1 mg) for 4 years following surgical menopause from hysterectomy and bilateral salpingo-oophorectomy at age 52 for benign ovarian cysts. She feels well with no menopausal symptoms. She has no other medical history and does not smoke. Her mother had breast cancer diagnosed at age 72. What is the most appropriate management regarding her HRT continuation?
According to UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the use of the combined oral contraceptive pill in a woman who is 6 weeks postpartum, fully breastfeeding, and has no other risk factors?
A 51-year-old woman presents with severe vasomotor symptoms including frequent hot flushes and night sweats that significantly impact her sleep and work performance. Her last menstrual period was 8 months ago. She has no significant medical history except for well-controlled hypothyroidism on levothyroxine. She underwent endometrial ablation 5 years ago for heavy menstrual bleeding. What is the most appropriate initial hormone replacement therapy regimen for this patient?
A 24-year-old woman attends for contraceptive advice. She currently uses condoms inconsistently and requests a reliable method. She has no medical history of note, takes no regular medications, is a non-smoker, and has a BMI of 23 kg/m². Her menstrual cycles are regular every 28 days. She mentions she often forgets to take daily medications and would prefer a method that doesn't require daily attention. What is the most appropriate contraceptive method to recommend?
A 50-year-old woman with a history of deep vein thrombosis 10 years ago (unprovoked) presents with severe vasomotor symptoms significantly affecting her quality of life. She has tried lifestyle modifications and cognitive behavioural therapy with minimal benefit. Her thrombophilia screen at the time was negative. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate management of her menopausal symptoms?
A 42-year-old woman with menorrhagia has been using a 52 mg levonorgestrel intrauterine system for 4 years with good effect. She now presents requesting early replacement as she has read that the device lasts 5 years for contraception but only 4 years for heavy menstrual bleeding. Her bleeding remains well controlled. What is the most appropriate advice?
A 35-year-old woman with a BMI of 38 kg/m² attends for review 6 months after insertion of a 52 mg levonorgestrel intrauterine system for contraception and heavy menstrual bleeding. She reports her bleeding has improved significantly but she has gained 4 kg weight since insertion. She is concerned the IUS is causing weight gain and requests removal. What is the most appropriate advice?
A 55-year-old woman presents for follow-up. She started continuous combined HRT (oral estradiol 1 mg with dydrogesterone 10 mg) 4 years ago for severe vasomotor symptoms. Her symptoms are now well controlled and she has no side effects. She has no personal history of breast cancer but her mother was diagnosed with breast cancer at age 68. Her BMI is 24 kg/m² and she is otherwise well. What is the most appropriate advice regarding continuation of HRT?
A 49-year-old woman started on sequential combined HRT (transdermal estradiol 50 mcg twice weekly with oral micronised progesterone 200 mg days 15-28) 3 months ago for perimenopausal symptoms. She is still having occasional irregular menstrual periods. She now reports breakthrough bleeding on day 10 of her cycle. What is the most appropriate initial management?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 11: A 47-year-old woman with regular menstrual cycles presents with worsening premenstrual mood symptoms including irritability, anxiety and low mood for 10 days before each period, which resolve shortly after menstruation begins. She also experiences moderate hot flushes in the week before her period. She requests effective contraception as she remains sexually active. Her BMI is 27 kg/m² and she has no significant medical history. What is the most appropriate management option?
- A. Copper intrauterine device for contraception plus sequential HRT
- B. 52 mg levonorgestrel intrauterine system for contraception plus cyclical progestogens
- C. Combined oral contraceptive pill taken continuously
- D. 52 mg levonorgestrel intrauterine system for contraception plus transdermal oestrogen patches (Correct Answer)
- E. Progestogen-only pill for contraception plus selective serotonin reuptake inhibitor
Explanation: ***52 mg levonorgestrel intrauterine system for contraception plus transdermal oestrogen patches***- The 52 mg **levonorgestrel intrauterine system (LNG-IUS)** provides highly effective **contraception** and necessary **endometrial protection**, while **transdermal oestrogen** manages perimenopausal vasomotor symptoms and stabilizes hormonal fluctuations associated with PMS.- This combination is ideal for a **perimenopausal** woman over 45 as it avoids its first-pass hepatic metabolism and effectively treats both the mood symptoms and **hot flushes**.*Copper intrauterine device for contraception plus sequential HRT*- While providing contraception, the **Copper IUD** does not assist in hormonal stabilization; **sequential HRT** maintains cyclical bleeding and hormonal peaks/troughs which can exacerbate **premenstrual mood symptoms**.- **Sequential progestogens** in HRT are often linked to the return or worsening of PMS-like symptoms during the progestogen phase.*52 mg levonorgestrel intrauterine system for contraception plus cyclical progestogens*- Using **cyclical progestogens** on top of an **LNG-IUS** is unnecessary and results in an excessive progestogen load without addressing the **oestrogen deficiency** causing her hot flushes.- This regimen fails to provide the **continuous oestrogen** needed to suppress the hypothalamic-pituitary-ovarian axis and stabilize mood symptoms.*Combined oral contraceptive pill taken continuously*- Although continuous **COCP** can suppress the cycle and stabilize mood, oestrogen-containing pills are generally transitioned to **HRT** as patients approach age 50 due to changing metabolic risks.- **Transdermal oestrogen** combined with an **IUS** is often preferred over the COCP in this age group (BMI 27, age 47) to minimize **venous thromboembolism (VTE)** risks.*Progestogen-only pill for contraception plus selective serotonin reuptake inhibitor*- While an **SSRI** can treat premenstrual dysphoria, it does not address the patient's **vasomotor symptoms** (hot flushes) caused by declining oestrogen levels.- The **progestogen-only pill (POP)** provides contraception but does not provide the **ovulation suppression** or hormonal stability as effectively as the LNG-IUS/oestrogen combination in perimenopause.
Question 12: A 56-year-old woman presents for review of her HRT. She has been taking continuous combined HRT (oral estradiol 2 mg with norethisterone acetate 1 mg) for 4 years following surgical menopause from hysterectomy and bilateral salpingo-oophorectomy at age 52 for benign ovarian cysts. She feels well with no menopausal symptoms. She has no other medical history and does not smoke. Her mother had breast cancer diagnosed at age 72. What is the most appropriate management regarding her HRT continuation?
- A. Continue HRT until at least age 60 given her premature surgical menopause
- B. Discontinue HRT immediately as she has exceeded the recommended duration
- C. Switch to oestrogen-only HRT as she has had a hysterectomy (Correct Answer)
- D. Reduce the dose of HRT to the lowest available strength
- E. Continue current HRT only if she develops recurrent symptoms after a trial of discontinuation
Explanation: ***Switch to oestrogen-only HRT as she has had a hysterectomy***- Women who have had a **hysterectomy** do not require a **progestogen** for **endometrial protection**; therefore, oestrogen-only therapy is the standard of care.- Removing the **norethisterone** (progestogen) is beneficial as progestogens are associated with a slightly higher risk of **breast cancer** compared to oestrogen-only HRT.*Continue HRT until at least age 60 given her premature surgical menopause*- While HRT is recommended until at least the **average age of menopause (51)**, continuing treatment is based on individual symptoms and risk profiles.- The primary issue here is the **incorrect formulation** (combined HRT) rather than just the duration of the therapy.*Discontinue HRT immediately as she has exceeded the recommended duration*- There is no arbitrary **time limit** for HRT; many women continue beyond age 51 to manage symptoms and for **bone protection**.- Sudden discontinuation may trigger the return of **vasomotor symptoms** and increase the risk of **osteoporotic fractures**.*Reduce the dose of HRT to the lowest available strength*- Dose reduction is a strategy for weaning, but it does not address the fundamental issue of unnecessary **progestogen exposure** in a woman without a uterus.- The patient is currently symptom-free, but her management must first be optimized by switching to the **safer oestrogen-only** profile.*Continue current HRT only if she develops recurrent symptoms after a trial of discontinuation*- A trial of discontinuation is not mandatory at age 56, especially since she should have been on a different **therapeutic regimen** (oestrogen-only) throughout.- This approach risks unnecessary exposure to **norethisterone**, which provides no benefit to this patient while increasing potential risks.
Question 13: According to UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), what category is assigned to the use of the combined oral contraceptive pill in a woman who is 6 weeks postpartum, fully breastfeeding, and has no other risk factors?
- A. UKMEC 1 - No restriction for use
- B. UKMEC 2 - Advantages generally outweigh risks
- C. UKMEC 3 - Risks generally outweigh advantages (Correct Answer)
- D. UKMEC 4 - Unacceptable health risk
- E. UKMEC 1 if breastfeeding established, UKMEC 2 if not
Explanation: ***UKMEC 3 - Risks generally outweigh advantages***- From **6 weeks to 6 months postpartum** in breastfeeding women, the **Combined Oral Contraceptive Pill (COCP)** is categorized as **UKMEC 3** because estrogen may negatively impact **milk volume** and quality.- While the risk of **Venous Thromboembolism (VTE)** has decreased compared to the immediate postpartum period, the potential impact on infant nutrition remains a concern.*UKMEC 1 - No restriction for use*- This category is reserved for methods that have no health restrictions, such as **Progestogen-only pills (POP)** or implants in breastfeeding women at this stage.- The **COCP** is never UKMEC 1 during active breastfeeding before 6 months due to hormonal interference with lactation.*UKMEC 2 - Advantages generally outweigh risks*- The COCP only becomes **UKMEC 2** for breastfeeding women after **6 months postpartum**, when the infant is likely consuming complementary foods.- It is also UKMEC 2 for **non-breastfeeding** women between 3 and 6 weeks postpartum if no other VTE risk factors are present.*UKMEC 4 - Unacceptable health risk*- The COCP is classified as **UKMEC 4** (absolute contraindication) for all women, regardless of breastfeeding status, during the first **21 days postpartum** due to the high risk of **VTE**.- For breastfeeding women specifically, it remains UKMEC 4 until **6 weeks postpartum** because of the combined risks of VTE and suppression of early lactation.*UKMEC 1 if breastfeeding established, UKMEC 2 if not*- This is not a standard UKMEC classification; eligibility is based on the **physiological timeframes** since delivery and the specific hormonal content of the contraceptive.- **Establishment of breastfeeding** does not waive the UKMEC 3 status of estrogen-containing methods between 6 weeks and 6 months.
Question 14: A 51-year-old woman presents with severe vasomotor symptoms including frequent hot flushes and night sweats that significantly impact her sleep and work performance. Her last menstrual period was 8 months ago. She has no significant medical history except for well-controlled hypothyroidism on levothyroxine. She underwent endometrial ablation 5 years ago for heavy menstrual bleeding. What is the most appropriate initial hormone replacement therapy regimen for this patient?
- A. Continuous combined HRT with oral estradiol and dydrogesterone (Correct Answer)
- B. Sequential combined HRT with transdermal estradiol and micronised progesterone
- C. Oestrogen-only HRT with transdermal estradiol patches
- D. Tibolone
- E. Vaginal oestrogen only
Explanation: ***Continuous combined HRT with oral estradiol and dydrogesterone*** - Even after **endometrial ablation**, the uterus remains in situ and the basal layer of the endometrium persists, necessitating **progestogen cover** to prevent endometrial hyperplasia and malignancy. - **Continuous combined HRT** is appropriate here as the patient is likely in the late **menopausal transition** (periods ceased for 8 months) or early postmenopause, and it avoids the withdrawal bleeds associated with sequential regimens. *Sequential combined HRT with transdermal estradiol and micronised progesterone* - **Sequential HRT** is typically indicated for perimenopausal women who are still having regular periods, to mimic a natural cycle and induce a monthly bleed. - This patient's last menstrual period was 8 months ago, indicating she is likely **postmenopausal or in late menopausal transition**, making continuous combined HRT more suitable to avoid regular, often unwanted, withdrawal bleeding. *Oestrogen-only HRT with transdermal estradiol patches* - This option is **contraindicated** because the patient has an **intact uterus** (even post-ablation), and unopposed oestrogen increases the risk of **endometrial hyperplasia and cancer**. - Endometrial ablation reduces the lining but does not remove all endometrial tissue, thus the need for progestogen cover remains for uterine protection. *Tibolone* - **Tibolone** is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties, used for vasomotor symptoms in postmenopausal women, but it is typically reserved for women at least **12 months post-menopause**. - While effective, it may not be the **most appropriate initial regimen** when a standard combined HRT is available and suitable for a patient who is 8 months since her LMP. *Vaginal oestrogen only* - **Vaginal oestrogen** therapy is primarily indicated for localised symptoms of **genitourinary syndrome of menopause (GSM)**, such as vaginal dryness, dyspareunia, and recurrent UTIs. - It provides **minimal systemic absorption** and would be ineffective in alleviating the patient's severe systemic **vasomotor symptoms** like hot flushes and night sweats.
Question 15: A 24-year-old woman attends for contraceptive advice. She currently uses condoms inconsistently and requests a reliable method. She has no medical history of note, takes no regular medications, is a non-smoker, and has a BMI of 23 kg/m². Her menstrual cycles are regular every 28 days. She mentions she often forgets to take daily medications and would prefer a method that doesn't require daily attention. What is the most appropriate contraceptive method to recommend?
- A. Combined oral contraceptive pill
- B. Progestogen-only pill
- C. Etonogestrel contraceptive implant (Correct Answer)
- D. Natural family planning
- E. Barrier methods with spermicide
Explanation: ***Etonogestrel contraceptive implant*** - This is a **Long-Acting Reversible Contraceptive (LARC)** that aligns with the patient's preference for a method requiring no daily attention and provides effective contraception for **three years**. - It boasts a very **high efficacy rate** (failure rate <0.1%) and is suitable for this patient with no contraindications, making it a highly reliable choice given her history of forgetting daily medications. *Combined oral contraceptive pill* - This method requires **daily administration** at a consistent time, which is not suitable for a patient who states she often forgets to take daily medications. - Its effectiveness is highly dependent on **user compliance**, making it less reliable for an individual with a history of inconsistent medication adherence. *Progestogen-only pill* - Similar to the combined pill, it requires **strict daily adherence**, often within a narrow time window (e.g., 3 hours for traditional POPs), which contradicts the patient's preference. - Given her history of **forgetting daily medications**, the risk of contraceptive failure with a progestogen-only pill is significantly increased. *Natural family planning* - This method demands **meticulous daily monitoring** of fertility signs (e.g., basal body temperature, cervical mucus), which is inconsistent with her desire for a method that doesn't require daily attention. - It has a significantly **higher typical-use failure rate** compared to LARC methods, making it a less reliable option for someone seeking a highly effective contraceptive. *Barrier methods with spermicide* - The patient already states she uses **condoms inconsistently**, indicating that methods requiring user action at the time of intercourse are not reliable for her. - While spermicide can increase efficacy slightly, these methods still require consistent and correct use with each act of intercourse and are **less effective** than hormonal options or LARCs.
Question 16: A 50-year-old woman with a history of deep vein thrombosis 10 years ago (unprovoked) presents with severe vasomotor symptoms significantly affecting her quality of life. She has tried lifestyle modifications and cognitive behavioural therapy with minimal benefit. Her thrombophilia screen at the time was negative. Her BMI is 26 kg/m² and she is a non-smoker. What is the most appropriate management of her menopausal symptoms?
- A. Prescribe transdermal estradiol with micronised progesterone as transdermal route has lower VTE risk
- B. Prescribe venlafaxine 75 mg daily as HRT is absolutely contraindicated (Correct Answer)
- C. Prescribe clonidine as a non-hormonal alternative to HRT
- D. Refer to haematology for assessment before considering any form of HRT
- E. Prescribe tibolone as it has a more favorable effect on coagulation than standard HRT
Explanation: ***Prescribe venlafaxine 75 mg daily as HRT is absolutely contraindicated*** - A history of **unprovoked venous thromboembolism (VTE)** is a **UKMEC 4** (absolute contraindication) for all forms of systemic hormone replacement therapy. - **Venlafaxine**, an SNRI, is an effective non-hormonal treatment that can reduce **vasomotor symptoms** by approximately 50-60%. *Prescribe transdermal estradiol with micronised progesterone as transdermal route has lower VTE risk* - While **transdermal HRT** does not increase VTE risk in the general population, it remains **contraindicated** in patients with a personal history of VTE. - Safety data for transdermal use in patients with prior **unprovoked clots** is insufficient to override the absolute contraindication. *Prescribe clonidine as a non-hormonal alternative to HRT* - **Clonidine** is often less effective than SSRIs or SNRIs for the relief of **vasomotor symptoms** and carries side effects like dry mouth and drowsiness. - It is generally considered a second-line non-hormonal option behind **venlafaxine** or gabapentin. *Refer to haematology for assessment before considering any form of HRT* - A **haematology referral** is unnecessary here because the clinical history of an **unprovoked VTE** already clearly defines the contraindication for HRT. - Guidelines advise against systemic HRT regardless of further **thrombophilia screening**, as previous clotting events are the strongest predictor of future risk. *Prescribe tibolone as it has a more favorable effect on coagulation than standard HRT* - **Tibolone** is a synthetic steroid that still carries a risk of **VTE and stroke**, making it unsuitable for this patient. - Like conventional systemic HRT, it is **contraindicated** in women with a personal history of thromboembolic disease.
Question 17: A 42-year-old woman with menorrhagia has been using a 52 mg levonorgestrel intrauterine system for 4 years with good effect. She now presents requesting early replacement as she has read that the device lasts 5 years for contraception but only 4 years for heavy menstrual bleeding. Her bleeding remains well controlled. What is the most appropriate advice?
- A. Replace the device now as it is only licensed for 4 years for heavy menstrual bleeding
- B. Replace the device at 5 years as per contraception licensing regardless of indication
- C. Reassure her that current evidence supports 5-year use for heavy menstrual bleeding (Correct Answer)
- D. Remove the device and trial tranexamic acid to see if it is still needed
- E. Add oral progestogen in the luteal phase to extend the device life
Explanation: ***Reassure her that current evidence supports 5-year use for heavy menstrual bleeding*** - Although historical licensing limits were lower, current **FSRH guidelines** and updated product licenses (e.g., **Mirena**) support the use of the **52 mg LNG-IUS** for 5 years for both **contraception** and **heavy menstrual bleeding (HMB)**. - Clinical evidence shows that **levonorgestrel levels** remain sufficient to provide effective **endometrial suppression** and bleeding control for the full 5-year duration. *Replace the device now as it is only licensed for 4 years for heavy menstrual bleeding* - This advice is outdated; while some older formulations had a 4-year license for HMB, modern **52 mg systems** are licensed for **5 years** across all indications. - Replacing the device early when bleeding is **well controlled** exposes the patient to unnecessary procedural risks such as **perforation** or **infection**. *Replace the device at 5 years as per contraception licensing regardless of indication* - While the replacement at 5 years is the correct timeframe, the rationale provided ignores that the **HMB indication** now also carries a 5-year recommendation. - It is important to reassure the patient that the efficacy for her specific condition (**menorrhagia**) matches the **contraceptive longevity**. *Remove the device and trial tranexamic acid to see if it is still needed* - **Tranexamic acid** is generally less effective than the **LNG-IUS** for managing HMB and would be a step down in therapy for a patient currently well-controlled. - Discontinuing a successful treatment without a clinical indication like **side effects** or the desire for pregnancy is not recommended. *Add oral progestogen in the luteal phase to extend the device life* - There is no clinical evidence to support adding **cyclical progestogens** to "extend" the life of an intrauterine system. - If an **LNG-IUS** is failing to control symptoms due to hormone depletion, the standard of care is **device replacement**, not supplementary oral therapy.
Question 18: A 35-year-old woman with a BMI of 38 kg/m² attends for review 6 months after insertion of a 52 mg levonorgestrel intrauterine system for contraception and heavy menstrual bleeding. She reports her bleeding has improved significantly but she has gained 4 kg weight since insertion. She is concerned the IUS is causing weight gain and requests removal. What is the most appropriate advice?
- A. Remove the IUS immediately as weight gain is a recognized side effect
- B. Explain that while weight gain is commonly reported, evidence does not support the LNG-IUS causing significant weight gain (Correct Answer)
- C. Offer to replace with copper IUD as this has no hormonal effects
- D. Arrange blood tests including thyroid function before making any changes
- E. Reduce dietary calories to 1200 kcal daily and review in 3 months
Explanation: ***Explain that while weight gain is commonly reported, evidence does not support the LNG-IUS causing significant weight gain*** - Clinical trials and systematic reviews consistently show no **causal relationship** between the **52 mg levonorgestrel intrauterine system (LNG-IUS)** and significant weight gain. - The **progestogen** in the LNG-IUS acts primarily **locally on the endometrium**, resulting in very low systemic levels compared to other hormonal contraceptives. *Remove the IUS immediately as weight gain is a recognized side effect* - Immediate removal is inappropriate without first discussing the lack of **clinical evidence** linking the IUS to weight changes. - The patient is benefiting significantly from the device for her **heavy menstrual bleeding**, and removal would lose these therapeutic benefits. *Offer to replace with copper IUD as this has no hormonal effects* - While a **copper IUD** is non-hormonal, it is known to increase **menstrual blood loss** and cramps, which would worsen the patient's primary complaint of heavy bleeding. - The LNG-IUS is the preferred **first-line treatment** for heavy menstrual bleeding, whereas the copper IUD is often contraindicated in such cases. *Arrange blood tests including thyroid function before making any changes* - While excluding **hypothyroidism** is reasonable in a patient with a high **BMI** and recent weight gain, it should not be the primary response to her concern about the IUS. - The main priority is to provide **evidence-based counseling** regarding her specific concern about the contraceptive device itself. *Reduce dietary calories to 1200 kcal daily and review in 3 months* - Recommending a specific, highly restrictive **1200 kcal diet** is often unsustainable and should be managed through structured **metabolic or nutritional services**. - This approach fails to address the patient's concern that the **contraceptive device** is the underlying cause of her physiological changes.
Question 19: A 55-year-old woman presents for follow-up. She started continuous combined HRT (oral estradiol 1 mg with dydrogesterone 10 mg) 4 years ago for severe vasomotor symptoms. Her symptoms are now well controlled and she has no side effects. She has no personal history of breast cancer but her mother was diagnosed with breast cancer at age 68. Her BMI is 24 kg/m² and she is otherwise well. What is the most appropriate advice regarding continuation of HRT?
- A. Continue HRT indefinitely as benefits outweigh risks with good symptom control
- B. Discontinue HRT immediately as she has exceeded 5 years of recommended use
- C. Discuss risks and benefits; consider trial of stopping or reducing dose if symptoms allow (Correct Answer)
- D. Switch to transdermal estrogen to reduce breast cancer risk before continuing
- E. Discontinue HRT due to family history of breast cancer
Explanation: ***Discuss risks and benefits; consider trial of stopping or reducing dose if symptoms allow*** - She has been on HRT for 4 years. It is crucial to **annually review** the **risk-benefit profile** of HRT, particularly as risks like **breast cancer** and **venous thromboembolism (VTE)** increase with duration of use. - A **trial of dose reduction** or stopping allows assessment of whether **vasomotor symptoms** have resolved, minimizing long-term exposure to potential risks while still managing symptoms if they recur. *Continue HRT indefinitely as benefits outweigh risks with good symptom control* - **Indefinite use** without regular re-evaluation is generally discouraged because the risks of **breast cancer** and **VTE** accumulate over time, even with good symptom control. - HRT should be used for the **shortest duration** necessary and at the **lowest effective dose** to manage symptoms, with periodic reassessment. *Discontinue HRT immediately as she has exceeded 5 years of recommended use* - There is **no arbitrary time limit** for HRT, and immediate cessation can lead to a sudden and severe recurrence of **menopausal symptoms**, negatively impacting quality of life. - Decisions to stop HRT should be a **shared process** between the patient and clinician, considering individual symptoms, risks, and benefits, rather than adherence to a fixed duration. *Switch to transdermal estrogen to reduce breast cancer risk before continuing* - While **transdermal estrogen** reduces the risk of **VTE** and stroke compared to oral forms, it does not significantly alter the **breast cancer risk** associated with combined HRT (estrogen plus progestogen). - The breast cancer risk in combined HRT is primarily linked to the **progestogen component** and duration of use, not solely the route of estrogen administration. *Discontinue HRT due to family history of breast cancer* - A mother diagnosed with breast cancer at age 68 represents only a **slightly increased baseline risk** for the patient and is not an absolute **contraindication** to HRT, especially if symptoms are well controlled. - **Family history** should be thoroughly discussed as part of the overall risk assessment, but it does not automatically mandate the cessation of HRT if the patient's personal risk profile remains acceptable.
Question 20: A 49-year-old woman started on sequential combined HRT (transdermal estradiol 50 mcg twice weekly with oral micronised progesterone 200 mg days 15-28) 3 months ago for perimenopausal symptoms. She is still having occasional irregular menstrual periods. She now reports breakthrough bleeding on day 10 of her cycle. What is the most appropriate initial management?
- A. Reassure and continue current regimen as irregular bleeding is common in first 3-6 months (Correct Answer)
- B. Switch to continuous combined HRT
- C. Arrange urgent transvaginal ultrasound and endometrial biopsy
- D. Increase the progestogen duration to days 1-14 each month
- E. Stop HRT and arrange investigation before restarting
Explanation: ***Reassure and continue current regimen as irregular bleeding is common in first 3-6 months*** - **Irregular bleeding** or breakthrough bleeding is common and expected in up to 80% of women during the **first 3-6 months** of Hormone Replacement Therapy (HRT) as the endometrium adjusts. - Since the patient is only **3 months** into her regimen and is still **perimenopausal**, the most appropriate initial step is to observe for resolution rather than rushing to investigations. *Switch to continuous combined HRT* - **Continuous combined HRT** is only indicated for women who are **postmenopausal** (at least one year since their last period) to avoid heavy and unpredictable bleeding. - Switching a **perimenopausal** woman with ongoing cycles to this regimen would likely worsen the frequency of **breakthrough bleeding**. *Arrange urgent transvaginal ultrasound and endometrial biopsy* - **Urgent investigations** for unscheduled bleeding are generally deferred until the bleeding persists beyond the **6-month adaptation period** or if there are high-risk red flags. - Initial management focuses on **clinical patience** unless the bleeding is unusually heavy or occurs in a postmenopausal woman on long-term therapy. *Increase the progestogen duration to days 1-14 each month* - **Sequential HRT** typically provides progestogen for 12–14 days in the second half of the cycle; changing the timing to days 1–14 does not align with standard **endometrial protection** protocols for perimenopausal women. - Adjusting the **progestogen dose or duration** is a secondary step considered only if bleeding persists or remains heavy after the initial stabilization phase. *Stop HRT and arrange investigation before restarting* - There is no clinical indication to **cease HRT** abruptly for breakthrough bleeding that has occurred for only 3 months in a perimenopausal patient. - Stopping therapy would likely lead to a recurrence of her **vasomotor/perimenopausal symptoms** without providing additional diagnostic clarity at this early stage.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free